PIONEER 6: a cardiovascular outcomes trial (CVOT) for RYBELSUS 1,2 Objective: Confirm treatment with RYBELSUS does not result in an unacceptable increase in CV risk compared to placebo (rule out 80% excess risk) in subjects with type 2 diabetes at high risk of CV events
You are reading a PlexusDx Education Hub article on GLP-1 and dual-agonist therapies, the programs that make them accessible, and the genetic details that underpin every metabolic choice
These changes, or reactions, can vary in type and severity
However, limited or no medical nutrition therapy (MNT) guidelines are provided to healthcare providers and patients regarding adequate nutrient intake during GLP-1RA use
You have candida, because candida produces acetaldehyde themselves, which is how a lot of alcohol is made, from yeast
In the meantime, there are licensed weight loss medicines available